Literature DB >> 32048201

Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates.

Lu Tan1, Tao Zheng1, Man Li1, Xiaofang Zhong1, Yao Tang1, Ming Qin1, Xun Sun2.   

Abstract

Messenger RNA (mRNA) vaccines have attracted great interest in recent years due to their high potency, safety profile, and potential of rapid development. Although a number of mRNA vaccines have entered clinical trials, there remain several challenges. Inefficient in vivo delivery of mRNA is the foremost one. Here we synthesized a conjugate composed of β-cyclodextrin (β-CD) and branched polyethyleneimine (molecular weight 2 kDa, bPEI2k) to deliver an mRNA vaccine. The CD-PEI (CP) conjugate helped the encapsulated mRNA molecules pass through the plasma membranes and escape from the endosomes, which consequently ensured high transfection efficiency. On this basis, we optimized several structural elements of mRNA molecules via synthesizing an advanced cap structure and incorporating untranslated regions (UTRs) and an extended poly(A) tail into the sequence. These modifications led to a higher expression level of encoded proteins, which was expected to induce potent immune responses with a relatively low dosage. We also investigated the relevance of the administration route to the immune responses induced by CP-assisted mRNA vaccines with in vivo evidence, providing a basis for the selection of optimum administration route in specific cases. This CP-based mRNA vaccine platform, with an optimized mRNA structure and administrated in a most appropriate route, holds a promise to be applied to specific antigens in the future. Graphical abstract.

Entities:  

Keywords:  Administration route; Cyclodextrin; Polyethyleneimine; mRNA structure; mRNA vaccine

Mesh:

Substances:

Year:  2020        PMID: 32048201     DOI: 10.1007/s13346-020-00725-4

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  12 in total

Review 1.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

Review 2.  Electrospun-Fibrous-Architecture-Mediated Non-Viral Gene Therapy Drug Delivery in Regenerative Medicine.

Authors:  Elena Cojocaru; Jana Ghitman; Raluca Stan
Journal:  Polymers (Basel)       Date:  2022-06-29       Impact factor: 4.967

Review 3.  mRNA vaccines for infectious diseases: principles, delivery and clinical translation.

Authors:  Namit Chaudhary; Drew Weissman; Kathryn A Whitehead
Journal:  Nat Rev Drug Discov       Date:  2021-08-25       Impact factor: 112.288

Review 4.  Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors:  Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal:  Mol Aspects Med       Date:  2021-08-05

Review 5.  Toward the prevention of coronavirus infection: what role can polymers play?

Authors:  X Jiang; Z Li; D J Young; M Liu; C Wu; Y-L Wu; X J Loh
Journal:  Mater Today Adv       Date:  2021-03-20

Review 6.  Drug delivery systems for RNA therapeutics.

Authors:  Kalina Paunovska; David Loughrey; James E Dahlman
Journal:  Nat Rev Genet       Date:  2022-01-04       Impact factor: 59.581

Review 7.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

Review 8.  Self-assembled mRNA vaccines.

Authors:  Jeonghwan Kim; Yulia Eygeris; Mohit Gupta; Gaurav Sahay
Journal:  Adv Drug Deliv Rev       Date:  2021-01-02       Impact factor: 17.873

Review 9.  In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?

Authors:  Ignasi Esteban; Carmen Pastor-Quiñones; Lorena Usero; Montserrat Plana; Felipe García; Lorna Leal
Journal:  Viruses       Date:  2021-03-18       Impact factor: 5.048

Review 10.  Cyclodextrins in Antiviral Therapeutics and Vaccines.

Authors:  Susana Santos Braga; Jéssica S Barbosa; Nádia E Santos; Firas El-Saleh; Filipe A Almeida Paz
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.